- Whatever Happened to the Microscope?March 01, 2014 | Thomas A. Bensinger, MD
Dr. Thomas Bensinger gives his views on why evaluation of the peripheral blood film is often not incorporated into the evaluation of hematology patients and offers solutions to remedy this glaring
- Letter to the EditorMarch 01, 2011 | March-April 2011, Volume 8, Issue 2
Dr. DiMichele outlined the appropriate evaluation that should be performed at presentation. She also gave sound counsel concerning the young woman's request for combined hormonal oral contraceptive pills, an effective treatment for menorrhagia, but complicated in this patient by the family history of thrombophilia. The wise advice here was avoidance of risk factors. The comprehensive nature of Dr. DiMichele's reply is evidenced in her noting the importance of the psychosocial, or quality-of-life, consequences for adolescents who must face these issues.
- NHLBI Clinical Trial for Treatment of TTPSeptember 01, 2009 | September-October 2009, Volume 6, Issue 5
The National Heart, Lung, and Blood Institute (NHLBI) Transfusion Medicine/Hemostasis Clinical Trials Network has opened a clinical trial to study the role of rituximab in the treatment of thrombotic thrombocytopenic purpura (TTP). The Network was formed in 2002 as a consortium of 18 academic centers to provide opportunities for clinical research on uncommon hematologic disorders.
- Hematology and GlycobiologyJuly 16, 2009 | July-August 2009, Volume 6, Issue 4
Earlier this year, the NHLBI convened a working group workshop on the roles of glycans in hemostasis, inflammation, and vascular biology. The Working Group Report has just been published in
- Poorer Patient Care: A Consequence of Increased Co-Pays and DeductiblesMarch 01, 2009 | March-April 2009, Volume 6, Issue 2
A greater part of the cost of medical care has shifted from insurance companies to the individual patient because of increases in co-pays and deductibles. A consequence of these increases is a change in patient behavior, which is rarely to his or her medical advantage.
- RE: 'The Wasteland of Relapsed Adult ALL'May 01, 2008 | May-June 2008, Volume 5, Issue 3
I have a few reservations with regard to Dr. Jerald Radich's article "
The Wasteland of Relapsed Adult ALL
" (March/April 2008 issue).
- Re: 'An ECO-Logical Way to Expand the Supply of Compatible Donor Red Blood Cells'September 01, 2007 | September-October 2007, Volume 4, Issue 5
I read with interest the article by Dr. Michael Linenberger
for the enzymatic conversion of red blood cell (RBC) antigens A, B, and AB to group O (ECO)
. However, the covalent attachment of poly(ethylene glycol) to RBCs (PEG-RBCs) to mask minor blood group antigens was presented as a competing technology that has not progressed due to technical limitations.
- RE: Corporate Support and Scientific IntegrityMay 01, 2007 | May-June 2007, Volume 4, Issue 3
I read with great interest and appreciation the
letter from Dr. Irwin Nash
in the March/April 2007 issue of
. The issue he described was one of the major reasons for ASH starting its Development Task Force, which I had the privilege to chair from 2003 to 2005. The idea was to try to get away from the Society's dependence on the drug and instrument companies, which have greatly enriched the Society's treasury.
- Corporate Support and Scientific IntegrityMarch 01, 2007 | March-April 2007, Volume 4, Issue 2
The medical industrial complex's compromising of academic medicine's scientific integrity is one of the most serious issues and problems for current day medical care. Any interested observer can pick out numerous clinical protocols whose design and aims were compromised by the need to come up with a result that would help sell a drug or device.